Pharmacotherapy Update Multiple Sclerosis
|
|
- Diana Davidson
- 5 years ago
- Views:
Transcription
1 Pharmacotherapy Update Multiple Sclerosis Yolande Hanssens SIG Leader Medicine Information Hamad Medical Corporation Pharmacy Department - Clinical Service Unit Doha - Qatar Heidelberg/October 2017 Pharmacotherapy Update Multiple Sclerosis Introduction Classification Therapeutic management of RRMS* Disease Modifying Drugs (DMDs) Patient tailored treatment Special patient groups Summary & take home messages *RRMS = Relapsing Remitting Multiple Sclerosis 1
2 MS - Intro Progressive, chronic idiopathic autoimmune driven disorder of the nervous system widespread inflammation affecting the brain and spinal cord plaques (MRI) Unpredictable Symptoms from numbness and tingling to blindness and paralysis Age 20-50, M:2F, genetic factors? North Europeans? > 2.3 million No cure MS Classification Relapsing-Remitting MS (RRMS) About 85% Secondary-Progressive MS (SPMS) Symptoms worsen more steadily over time, with or without the occurrence of relapses and remissions. RRMS SPMS at some point Primary-Progressive MS (PPMS) About 10% slowly worsening symptoms from the beginning, with no relapses or remissions Progressive-Relapsing MS (PRMS) About 5% steadily worsening disease state from the beginning, with acute relapses but no remissions, with or without recovery Hooper K. Managing Progressive MS. New York, NY: National Multiple Sclerosis Society; Multiple Sclerosis: Just the Facts New York, NY; National Multiple Sclerosis Society;
3 Types of MS at Diagnosis MS International Federation; Clinical Evolution TIME WINDOW to START TREATMENT RIS = Radiological Isolated Syndrome CIS = Clinical Isolated Syndrome RRMS = Relapsing Remitting MS R-SPMS = Relapsing Secondary Progressive MS SPMS = Secondary Progressive MS 3
4 Therapeutic Management No Cure DMDs for RRMS Mode of Action & Major Adverse Events Documented Treatment Effects Patient Tailored Therapy Special Patient groups & Overall Pharmaceutical Care Considerations DMD = Disease modifying Drug RRMS = Relapsing Remitting MS Ocreluzimab i.v EDDS = Expanded Disability Status Scale MSFC = Multiple Sclerosis Functional Composite NEDA = No Evidence of Disease Activity 4
5 DMDs for RRMS Interferon β (Rebif, Betaseron, Avonex, Plegridy ) Glatiramer acetate (Copaxone ) Teriflunomide (Aubagio ) Dimethyl fumarate (Tecfidera ) Fingolimod (Gilenya ) Natalizumab (Tysabri ) Alemtuzumab (Lemtrada ) Ocrelizumab (Ocrevus ) DMD = Disease modifying Drug RRMS = Relapsing Remitting MS MOA - unknown Interferon β (PEG)Interferon Beta-1a IM (Avonex ) & SubQ (Rebif, Plegridy ) Chinese hamster ovary cells Interferon Beta-1b SubQ (Betaseron ) E coli 5
6 Interferon β - Concerns Related to adverse effects Anaphylaxis/hypersensitivity reactions Autoimmune disorders Bone marrow suppression Flu-like symptoms Hepatic effects obtain liver function tests at 1, 3, and 6 months post therapy initiation and periodically thereafter. Injection site reactions Neuropsychiatric disorders Thrombotic microangiopathy Glatiramer Acetate MOA - thought to induce and activate T-lymphocyte suppressor cells specific for a myelin antigen & to interfere with the antigen-presenting function of certain immune cells opposing pathogenic T-cell function SubQ - 20 mg once daily OR 40 mg 3x/week 6
7 Glatiramer - Concerns Related to adverse effects Hypersensitivity reactions Immune response Lipoatrophy including skin necrosis Systemic reactions anxiety, chest pain, constriction of the throat, dyspnea, flushing, palpitations, urticaria usually self-limited and transient generally occur several months after initiation of treatment. Teriflunomide MOA - immunomodulatory agent that inhibits pyrimidine synthesis, resulting in antiproliferative and anti-inflammatory effects - may reduce the number of activated lymphocytes in the CNS PO 7 to 14 mg once daily 7
8 Teriflunomide - Concerns Related to adverse effects Dermatologic reactions: Cases of serious skin reactions, including cases of Stevens-Johnson syndrome and fatal toxic epidermal necrolysis have been reported with teriflunomide Hepatotoxicity - [US Boxed Warning] Hypersensitivity reactions - Anaphylaxis and severe allergic reactions may occur Hypertension Infections Interstitial lung disease Malignancy Pancreatitis Peripheral neuropathy Renal effects - Transient acute renal failure Teriflunomide - Concerns Other Drug elimination procedure - up to 2 years to reach low levels of teriflunomide metabolite serum concentrations. drug elimination procedure using cholestyramine or activated charcoal for more rapid elimination BUT return of disease activity Teriflunomide is also found in semen Immunizations - before initiating therapy 8
9 Dimethyl fumarate MOA - believed to result from its anti-inflammatory and cytoprotective properties via activation of the Nrf2* pathway PO 120 mg BID; after 7 days to 240 mg BID *Nrf2 = nuclear factor (erythroid-derived 2)-like 2 Dimethyl fumarate - Concerns Related to adverse effects Dermatitis/irritation Flushing Gastrointestinal events Hepatotoxicity Hypersensitivity reactions- Anaphylaxis and angioedema may occur after the first dose or at any time during treatment Lymphopenia Proteinuria Progressive multifocal leukoencephalopathy (PML) - 9
10 Dimethyl fumarate - Concerns Related to adverse effects Dermatitis/irritation Flushing Gastrointestinal events Hepatotoxicity Hypersensitivity reactions Lymphopenia Proteinuria Progressive multifocal leukoencephalopathy (PML) associated with persistent (>6 months) lymphopenia, with a majority of cases occurring in patients with lymphocyte counts <500/mm 3 and anti-jcv (John Cunningham virus) antibody >0.9 withhold therapy immediately at the first sign or symptom suggestive of PML (eg, progressive weakness on one side of the body or clumsiness of limbs; vision disturbances; mental status changes) and perform a diagnostic evaluation (MRI findings may appear before clinical signs/symptoms). Fingolimod MOA Sphingosine 1-Phosphate (S1P) Receptor Modulator; blocks the lymphocytes' ability to emerge from lymph nodes the amount of lymphocytes available to the central nervous system is decreased reduces central inflammation. PO 0.5 mg PO once daily 10
11 Fingolimod- Concerns Related to adverse effects Atrioventricular (AV) block Bradycardia Cryptococcal infections Hepatic effects Herpes infection Hypersensitivity reaction Hypertension Immune suppression Macular edema Malignancy Neurotoxicity Progressive multifocal leukoencephalopathy (PML) Respiratory effects QT prolongation Fingolimod- Concerns Other specific warnings/precautions Discontinuation of therapy rebound syndrome may occur within 4 to 16 weeks of stopping fingolimod treatment in patients with multiple sclerosis of varying severity and duration relapses have occurred despite the initiation of other diseasemodifying therapies Rebound symptoms: back and extremity pain, confusion, constipation, diplopia, facial muscle spasms, fatigue, increased leg weakness, nausea, paraparesis and paresthesias 11
12 Natalizumab Alemtuzumab Ocrelizumab Monoclonal Antibodies with different MOA IV with different treatment schedules Natalizumab : 300 mg every 4 weeks Alemtuzumab : 12 mg daily for 5 consecutive days (total 60 mg), followed 12 months later by 12 mg daily for 3 consecutive days (total 36 mg); total duration of therapy: 24 months Ocrelizumab : 300 mg on day 1, 300 mg 2 weeks later and 600 mg once every 6 months Natalizumab Alemtuzumab Ocrelizumab Monoclonal Antibodies with different MOA Need for pre-medication methylprednisolone (1000 mg IV) 30 minutes prior to each infusion an antihistamine (eg, diphenhydramine) 30 to 60 minutes prior each infusion may also consider premedication with paracetamol assess for infection; delay administration for active infection monitor patient during (and after) infusion 12
13 Natalizumab, Alemtuzumab Ocrelizumab - Concerns Related to adverse effects Hepatotoxicity Herpes infection & other infections Hep B reactivations Hypersensitivity reaction/antibody formation Immune reconstitution inflammatory syndrome (IRIS) Malignancy Lab test abnormalities Progressive multifocal leukoencephalopathy (PML) Auto-Immune effects Bone marrow suppression GI toxicity Ocreluzimab i.v EDDS = Expanded Disability Status Scale MSFC = Multiple Sclerosis Functional Composite NEDA = No Evidence of Disease Activity 13
14 Overview of the efficacy of MS therapies currently available: NEDA # at 2 years Trial Study drug % patients achieving NEDA # Comparator % patients achieving NEDA # OPERA I 1*** Ocrelizumab 48 sc IFN β-1a 29 OPERA II 1*** Ocrelizumab 48 sc IFN β-1a 25 CARE-MS I 2* Alemtuzumab 39 sc IFN β-1a 27 AFFIRM 3*** Natalizumab 37 Placebo 7 FREEDOMS 4** Fingolimod 33 Placebo 13 CARE-MS II 5*** Alemtuzumab 32 sc IFN β-1a 14 DEFINE 6* Dimethyl fumarate 28 Placebo 15 TEMSO 7** Teriflunomide 22.9 Placebo 14.3 Data cannot be directly compared between trials because of different study designs and/or populations P-value study drug vs comparator; *<0.05; **<0.001; ***< Traboulsee A et al. Neurology 2016;86 [PL02.004]; 2. Cohen AJ et al. Lancet 2012;380: ; 3. Havrdova E et al. Lancet Neurol 2009;8:254 60; 4. Bevan CJ, Cree BAC. JAMA Neurol 2014;71:269 70; 5. Coles AJ et al. Lancet 2012;380: ; 6. Giovannoni G et al. Neurology 2012;78 [PD5.005]; 7. Freedman M et al. Neurology 2012;78 [PD5.007] # NEDA = No Evidence of Disease Activity 14
15 Comi G, Radaelli M, Soelberg Sorensen P. Lancet 2017;389:
16 Switching Therapy &Wash-Out Periods Required for Treatment Switch in MS Patients Treatment 1 Treatment 2 Wash-Out IFN 1 or GA 2 Any Drug No wash-out required Any Drug IFN or GA No wash-out required Teriflunomide Dimethyl Fumarate Fingolimod Natalizumab Fingolimod Natalizumab Alemtuzumab Fingolimod Natalizumab Alemtuzumab Teriflunomide Natalizumab Alemtuzumab Fingolimod Teriflunomide Dimethyl Fumarate accelerated elimination procedure or 3.5 months until lymphocytes level returns to normal levels until lymphocytes level returns to normal levels (1 to 2months) 1-3 months 1 IFN = Interferon; 2 GA = Glatiramer Acetate Michel L, et al. Update on treatments in multiple sclerosis. Presse Med
17 Treatment decisions for RRMS are multifactorial: Need for Systematic Approach Patient & Disease Profile Therapy Issues Patient Preferences Geographic & Economic Factors Age, gender, family status Disease activity/disease type Stage of disease Treatment history Comorbidities & concurrent treatment Efficacy Safety Tolerability Administration (route/frequency) Monitoring requirements & frequency of monitoring Sociodemographic profile (lifestyle, work status, family status) Convenience Risk tolerance Likelihood of adherence Access to medication Approved usage Cost Female Pregnancy Lactation Shared Decision & Patient Tailored Treatment MS & Pregnancy Effects of pregnancy on MS Rate of relapse especially during 3 rd trimester Rate of relapses in first 3 months post partum Before 1 st Trim 2 nd Trim 3 rd Trim 1 st 3 months post Confavreux C et al. NEJM. 1998: Vukusic S et al. Brain. 2004:
18 MS & Pregnancy Effects of pregnancy on MS No acceleration in the rate of disability or disease progression postpartum Epidural anesthesia Breastfeeding No adverse event on rate of relapse or progression of MS Confavreux C et al. NEJM. 1998: Vukusic S et al. Brain. 2004: MS & Pregnancy MS does not seem to impair fertility Effect of Assisted Reproductive Technology (ART)? risk of MS disease activity? Roles of extra hormones (GnRH agonist, FSH, progesterone) or rapid changes in hormone levels Hellwig K, Correale. J Clin Immunol. 2013: Correale J et al. Ann Neurol. 2012: Voskuhl RR. Ann Neurol. 2012:631 18
19 MS & Pregnancy Effect of MS on Pregnancy Outcomes rate of caesarian delivery Lower infant birth weight No in complications ectopic pregnancies birth defects spontaneous abortions MS in offspring : 2.5% (single MS) vs 30.5% (dual MS) Kelly VM et al. Neurology. 2009: Dahl J et al. Neurology. 2005: Mueller BA et al. Am J Obstet Gynecol. 2002: Ebers G. Lancet Neurol. 2008: MS & Pregnancy Treatment of RRMS during Pregnancy To stop or NOT to stop? Washout period DMD Glatiramer acetate Interferons Dimethyl fumarate Natalizumab Fingolimod Alemtuzumab Teriflunomide* Washout period none zero to one month zero to one month one to three months two months three to four months washout protocol using po cholestyramine or activated charcoal (<0.02mg/ml) *Also found in semen 19
20 Safety during pregnancy of drugs used to treat RRMS Category B - No evidence of human risk in controlled studies Glatiramer acetate Category C - Risk cannot be ruled out Alemtuzumab Dimethyl fumarate Fingolimod Interferon beta-1a (Avonex, Rebif ) Interferon beta-1b (Betaseron ) Natalizumab Category X - Contraindicated in pregnancy Teriflunomide Modified from: Damek DM, Shuster EA, Mayo Clin Proc 1997; 72:977 (UptoDate-SEP2017) MS & Breastfeeding Effect of breastfeeding on MS None Effect of MS on breastfeeding Meds! Interferon β and glatiramer acetate OK? Others to avoid Coyle PK. Continuum (Minneap Minn). 2014:42-59 Hale TW et al. Breastfeed Med. 2012:
21 Conclusions Management of patients with MS/RRMS is very complex Early treatment influences the course over time There is a clear difference in safety profile among the current DMDs The risk-benefit ratio needs to be individualized Baseline assessment and monitoring are required for most of the DMDs in MS Teratogenicity & carcinogenicity are important factors in the choice of DMD Cost 21
MULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationTREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center
TREATING MULTIPLE SCLEROSIS 2018 The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center Welcome Thank you for joining us! Today you will learn about MS treatment choices
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationClass Update with New Drug Evaluation: Disease-Modifying Drugs for Multiple Sclerosis
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationObjectives. There Aren t Enough Hours in the Day
There Aren t Enough Hours in the Day Medication monitoring and communication of results Objectives Review the types of testing being ordered on patients receiving therapies other than platforms Discuss
More informationPage 1. Multiple Sclerosis. I have no conflicts of interest. Team Menstrual Cycles Waves to Wine for MS. Overview.
Multiple Sclerosis New Developments Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Team Menstrual
More informationOcrevus. (ocrelizumab) New Product Slideshow
Ocrevus (ocrelizumab) New Product Slideshow Introduction Brand name: Ocrevus Generic name: Ocrelizumab Pharmacological class: CD20-directed cytolytic monoclonal antibody Strength and Formulation: 30mg/mL;
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.09 Subject: Aubagio Page: 1 of 6 Last Review Date: June 22, 2017 Aubagio Description Aubagio (teriflunomide)
More informationDo you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No
The following survey will ask you questions about your family history of MS, your MS diagnosis and history, your symptoms, and your treatments. You may find it easier to fully answer these questions if
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subsection: Endocrine and Metabolic Drugs Original Policy Date: April 1, 2013 Subject: Aubagio
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationDisease-modifying therapies
Updated May 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. For some people, a diagnosis of multiple sclerosis (MS) is a relief, giving a name and a reason
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationUNDERSTANDING HAIR THINNING/HAIR LOSS
UNDERSTANDING HAIR THINNING/HAIR LOSS INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING: HEPATOTOXICITY
More informationWelcome to todays Webinar
Welcome to todays Webinar Your Presenter is: Lyndal Emery Your Facilitator is: Andrea Salmon Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands
More informationKristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University
Kristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University Harrison School of Pharmacy Auburn, Alabama Presenter:
More informationDISEASE-MODIFYING THERAPIES FOR MS
DISEASE-MODIFYING THERAPIES FOR MS Updated December 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. A multiple sclerosis (MS) diagnosis can bring a sense
More informationAnticipated Launches Q Q1 2019
Anticipated Launches Q4 2018-Q1 2019 Disease Prevalence Amyloidosis Tegsedi (inotersen) subcutaneous (SC) injection Akcea s/ionis Pharmaceuticals hereditary transthyretin amyloidosis (hattr) with polyneuropathy,
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationFAMILY PLANNING AND AUBAGIO (teriflunomide)
FAMILY PLANNING AND AUBAGIO (teriflunomide) INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING:
More informationSUBHAN ALLAH US/CANADIAN PHARMACY EXAMS EDNAN UNDERSTANDING MULTIPLE SCLEROSIS (MS) COPY RIGHT PROTECTED Page 1
UNDERSTANDING MULTIPLE SCLEROSIS (MS) Pathogenesis: Multiple sclerosis (MS) is the most common immune-mediated disease of the central nervous system (CNS) that specifically affects the nerves in the brain,
More informationGet on with life, we ll see you. in 6 months. Living your life your way with MS
Get on with life, we ll see you in 6 months. Living your life your way with MS If you re one of the 4000 New Zealanders affected by MS, ask your doctor or nurse if OCREVUS is right for you. Contents What
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationMultiple Sclerosis Update
Multiple Sclerosis Update Amanda Stahnke, PharmD, BCACP University of Missouri-Kansas City School of Pharmacy Kansas City Veterans Affairs Honor Annex Kelsey Morris, PharmD University of Kansas Health-System
More informationLocal Natalizumab Treatment Protocol
Local Natalizumab Treatment Protocol 1. New medicine name: Natalizumab 300mg concentrate for solution for infusion (Natalizumab ) 2. Licensed indication(s): Natalizumab is indicated for single disease
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationMultiple Sclerosis: Emerging Therapies
Multiple Sclerosis: Emerging Therapies Bruce Cree, MD, PhD, MCR Conflicts of Interest EMD Serono: Grant support ovartis: Adviser, Clinical Trial Participant What are the Future Considerations for MS Therapies?
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationMellen Center Approaches: Natalizumab
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Natalizumab Who should be considered for Natalizumab therapy? In the phase II and phase
More informationWelcome to today s webinar: Learn about MS
Welcome to today s webinar: Learn about MS Your Presenter is Dr Todd Hardy Your Facilitator is Belinda Saunders Housekeeping Thanks for joining us for this webinar welcome! You will be able to: hear the
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationMultiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1
Multiple Sclerosis Introduction Multiple sclerosis, or MS, is a disease of the brain and spinal cord. Most patients with multiple sclerosis are able to lead a very functional life. However, MS causes a
More informationMultiple Sclerosis. Stanley L Cohan, MD, PhD Providence MS Center Providence Brain and Spine Institute
Stanley L Cohan, MD, PhD Providence MS Center Providence Brain and Spine Institute 1 Stanley Cohan conflicts of interest Research Support: Biogen Idec, Novartis, Mallinkrodt, Genzyme, Sanofi-Aventis, Teva,
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDISCLAIMER FDA INDICATIONS INITIAL COVERAGE CRITERIA POSITION STATEMENT. Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013
Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013 Policy Number: MCP-146 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP)
More informationTRANSPARENCY COMMITTEE Opinion 05 March 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 05 March 2014 AUBAGIO 14 mg, film-coated tablet B/28 tablets (CIP: 3400927499890) Applicant: GENZYME SAS INN ATC code
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMultiple Sclerosis Therapeutics Update. James Bowen, MD Multiple Sclerosis Center Swedish Neuroscience Institute
Multiple Sclerosis Therapeutics Update. James Bowen, MD Multiple Sclerosis Center Swedish Neuroscience Institute 1 Current MS Treatments Interferons IFN 1-b Betaseron, Extavia IFN 1-a Intramuscular: Avonex
More informationMultiple Sclerosis: More Than Your ABC s. Technician Objectives. Pharmacist Objectives. Pretest Question. Pretest Question 9/22/16
Disclosure and Conflict of Interest Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HNMC.CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Medi-Cal Coding Implications Revision Log See Important Reminder
More informationMultiple Sclerosis. What types of MS are there? 4 There are 4 types of MS.
Multiple Sclerosis What is Multiple Sclerosis? 1,2 Multiple Sclerosis (MS) is a nervous system disease that affects the brain and spinal cord. The cause of MS is unknown. But, many investigators believe
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.CPA.334 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Novantrone) Reference Number: CP.CPA.334 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationSubject: Natalizumab (Tysabri ) IV
09-J0000-73 Original Effective Date: 03/15/08 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Natalizumab (Tysabri ) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets)
Your Contact Friederike Segeberg +49 6151 72-6328 Investor Relations +49 6151 72-3321 August 25, 2017 European Commission Grants Approval for Mavenclad (Cladribine Tablets) First oral short-course treatment
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.PHAR.258 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Novantrone) Reference Number: CP.PHAR.258 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationImproving Patient Outcomes with Novel Treatment Strategies in the Management of Multiple Sclerosis. Gary M. Owens, MD April 27, 2017
Improving Patient Outcomes with Novel Treatment Strategies in the Management of Multiple Sclerosis Gary M. Owens, MD April 27, 2017 1 Discussion Outline Brief MS background and disease state review Diagnosing
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationPrior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:
06/01/2016 Prior Authorization Aetna Better Health Michigan Gilenya This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 11.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationMultiple sclerosis (MS) is a
THERAPY UPDATE ar Layar Oral disease-modifying therapies for relapsing-remitting multiple sclerosis Rachel Hutchins Thomas and Richard A. Wakefield Purpose. The efficacy and safety of the three oral agents
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationMULTIPLE SCLEROSIS Management and Therapy
MULTIPLE SCLEROSIS Management and Therapy 115 th Oklahoma Osteopathic Association Annual Convention April 30 th, 2015 Anthony J. Vaughn, M.D. ANTHONY J. VAUGHN, M.D. Assistant Professor Director, Clinical
More informationMultiple Sclerosis. Biology 12 Nervous System Project
Multiple Sclerosis Biology 12 Nervous System Project Overview Multiple Sclerosis (MS) is a progressive and unpredictable disorder that affects the central nervous system. Figure 1: The central nervous
More informationAlemtuzumab Clinical Information for Nurses. Lemtrada
Alemtuzumab Clinical Information for Nurses Lemtrada Objectives Upon completion of this program, the learner will: Understand mechanism of action of Lemtrada Identify appropriate clinical situations for
More informationAmirmasoud Nikahd. Advisory Committee Researcher in Dena Clinical Research Consultants, Toronto.
Recent Trends in Treatment of Multiple Sclerosis: An Oral Medication: Gilenya --------------------------------------------------------------------------------------------------------------------------------
More informationDemyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow
Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow Reading: Robbins & Cotran, 9 th edition, pp 1283-1286 Robbins Basic Pathology, 9 th edition, 832-835 Overview: Grossly, myelin is
More informationOcrevus (ocrelizumab)
Ocrevus (ocrelizumab) Policy Number: 5.01.629 Last Review: 04/2018 Origination: 05/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Ocrevus
More informationOCREVUS TM (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OCREVUS safely and effectively. See full prescribing information for OCREVUS. OCREVUS TM (ocrelizumab)
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationTYSABRI (natalizumab) BENEFIT INVESTIGATION WORKSHEET GUIDE
TYSABRI (natalizumab) BENEFIT INVESTIGATION WORKSHEET GUIDE TYSABRI is administered intravenously by a healthcare professional once every 4 weeks. Therefore, a patient treated with TYSABRI will need to
More informationNEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS
NEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS Learning Objectives Daniel Harrison, MD University of Maryland School of Medicine Baltimore, MD Upon completion of this module, participants should be familiar with:
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ampyra (dalfampridine) Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ampyra (dalfampridine) Prime Therapeutics will review Prior Authorization
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationOCREVUS (ocrelizumab) Injection, for Intravenous Use
OCREVUS (ocrelizumab) Injection, for Intravenous Use Heidi Crayton, MD Medical Director Multiple Sclerosis Center of Greater Washington Vienna, VA OCR/071916/0181(1) Disclaimer This program is presented
More informationHorizon Scanning Centre July Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711
Horizon Scanning Centre July 2014 Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711 This briefing is based on information available at the time of research and a limited
More informationDimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
H.P. Acthar Gel (repository corticotropin) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: H.P. Acthar Gel (repository corticotropin) Prime Therapeutics
More informationRegulatory Status FDA-approved indication: Tecfidera is indicated for the treatment of patients with relapsing forms of multiple sclerosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.01 Subject: Tecfidera Page: 1 of 5 Last Review Date: December 2, 2016 Tecfidera Description Tecfidera
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationMultiple Sclerosis (MS) Dr Oliver Lily Consultant Neurologist Leeds General Infirmary
Multiple Sclerosis (MS) Dr Oliver Lily Consultant Neurologist Leeds General Infirmary Multiple sclerosis What is MS? What causes MS? Symptoms and signs of MS Making the diagnosis Investigations Treatments
More informationnatalizumab (Tysabri )
natalizumab (Tysabri ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),
More informationInfusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis
Infusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis 1 PREINFUSION COUNSELING Provide medication guide and review with your patient Inform patients about the signs
More informationTYSABRI Treatment Initiation Form
TYSABRI Treatment Initiation Form This form should be read carefully before starting treatment with TYSABRI. Please follow the advice in this form to ensure that you are fully informed of, and understand
More informationFingolimod (Gilenya) What is fingolimod? Can I have this drug?
Fingolimod (Gilenya) This factsheet is about fingolimod, a disease modifying therapy (DMT) for relapsing multiple sclerosis (MS). At the end of this factsheet you ll find out where you can get more information
More informationRegulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.27 1 of 6 Last Review Date: December 5, 2014 Tysabri Description Tysabri (natalizumab) Background
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION ALEMTUZUMAB (Lemtrada Genzyme Canada) Indication: Relapsing-Remitting Multiple Sclerosis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that alemtuzumab
More informationFor all requests for Multiple Sclerosis Medications all of the following criteria must be met:
Request for Prior Authorization for Multiple Sclerosis Medications Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Multiple Sclerosis Medications require
More information